Liposome-Loaded Immune Cells Cross Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering pharmaceutical agents across blood barriers, such as the blood-brain barrier, are inefficient and often invasive, leading to superficial distribution and increased side effects, with existing strategies like high dosing and nanoparticle systems facing challenges in effectively targeting and penetrating these barriers without disrupting them.
Innovation Solution
Administering liposomes that accumulate in immune cells, such as macrophages and monocytes, to activate them and cross the blood-brain barrier, allowing for targeted delivery of pharmaceutical agents to the brain and other protected organs without disrupting the barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high dosing is used to overcome inefficient delivery, then the delivery efficiency is improved, but serious potential side effects increase
Solution Approach 1:
The patent uses liposomes as intermediary carriers to transport pharmaceutical agents across the blood-brain barrier. The liposomes are taken up by immune cells (macrophages and monocytes) that naturally traverse the BBB, thereby mediating drug delivery without requiring high doses that would cause systemic side effects.
Solution Approach 2:
The invention exploits the natural behavior of immune cells to cross the blood-brain barrier and deliver liposome-encapsulated drugs. The immune cells self-transport the therapeutic agent across the barrier without external intervention, achieving efficient delivery at lower doses.
2Productivity
If transient osmotic opening of the BBB is used, then drug delivery is improved, but the procedure becomes invasive
Solution Approach 1:
Instead of directly opening the BBB through invasive procedures, the patent uses liposome-loaded immune cells as intermediaries that naturally cross the intact barrier. This mediates drug delivery without disrupting barrier integrity or requiring invasive surgical intervention.
3Manufacturing precision
If nanoparticle systems are used to deliver drugs, then targeted delivery is improved, but the distribution becomes superficial
Solution Approach 1:
The patent employs immune cells that naturally migrate through the blood-brain barrier and distribute throughout the brain tissue. This self-migration mechanism ensures deep and widespread distribution of the therapeutic agent, overcoming the superficial distribution limitation of conventional nanoparticle systems.
4Productivity
If lipophilic precursors are administered to cross the BBB, then drug delivery is improved, but uptake by other tissues increases resulting in toxicity
Solution Approach 1:
The patent uses liposomes (flexible lipid bilayer shells) to encapsulate pharmaceutical agents. This flexible shell structure allows the drugs to be transported in their original form without requiring lipophilic modification, thereby achieving BBB crossing while preventing off-target tissue uptake and toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables effective and targeted delivery of pharmaceutical agents across blood barriers, reducing side effects and improving the distribution of therapeutic agents to the brain and other protected organs, while maintaining the integrity of the blood-brain barrier.
Implementation Method 1
the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells
Data Source
AI summary
A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.